Levebon (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal membranes and decreases abnormal neuronal excitability, thereby preventing the initiation and spread of epileptic seizures without directly influencing ion channels or GABA receptors.

The appropriate dose of Levebon is determined individually by a qualified prescriber based on the patient’s age, seizure type, renal function and overall clinical condition. Dosage regimens are tailored to achieve optimal seizure control while minimizing adverse effects.

Levetiracetam’s pregnancy category is listed as unknown, and safety data for breastfeeding are limited. Healthcare providers should evaluate the potential benefits against possible risks and discuss alternative options with patients who are pregnant or nursing.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levebon (levetiracetam) offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproic acid. It is generally well‑tolerated, has fewer drug‑enzyme interactions, and may be preferred when rapid titration or minimal hepatic metabolism is desired.

Levebon should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Levebon is taken orally, usually as a tablet, with or without food. The exact administration schedule—once daily or twice daily—depends on the prescriber’s instructions and the patient’s therapeutic needs.

Serious risks include severe allergic reactions such as anaphylaxis, skin disorders like Stevens‑Johnson syndrome, and neuropsychiatric events such as suicidal thoughts or severe depression. Patients should be monitored closely for any new or worsening symptoms and seek immediate medical attention if serious reactions occur.

Levebon is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting enzyme‑inducing antiepileptic drugs without appropriate monitoring.